Tradestie Institutional Equity Comparison Engine
ENTX vs LYRA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ENTX Overall Edge
ENTX Captures Institutional Edge (3โ0 Pillars ยท 6โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Entera Bio Ltd. Ordinary Shares (ENTX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ENTX trades at N/M Forward P/E with 0.0% operating margin (-100.0% YoY revenue) versus LYRA at N/M Forward P/E and -25032.0% operating margin (-87.2% YoY). In options structure, ENTX sits in CONSOLIDATION (32nd %ile IV; Dealer Gamma Walls on Pro) against LYRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
ENTX N/M vs LYRA N/M Fwd P/E
Growth & Margin Winner
ENTX
Op Margin 0.0% vs -25032.0% ยท YoY -100.0% vs -87.2%
Momentum & Technical Winner
ENTX
1Y +11.1% vs -94.3% ยท 52W Pos 64% vs 1%
Options & Structure Winner
ENTX
CONSOLIDATION (32nd %ile IV) vs UNCLASSIFIED (N/A IV)
ENTX
NASDAQ
Entera Bio Ltd. Ordinary Shares
Biological Products, (No Disgnostic Substances)
$3.01
-0.33% 1D
Market Cap
$541.6M
1M Return
+2.38%
1Y Return
+11.07%
Forward P/E
N/M
Unified AI Score
53.5 / 100
HOLD
Tech 35.0
Fund 55.0
Flow 72.0
Mom 60.0
LYRA
NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap
$2.3M
1M Return
-62.5%
1Y Return
-94.34%
Forward P/E
N/M
Unified AI Score
52.2 / 100
HOLD
Tech 60.0
Fund 56.0
Flow 50.0
Mom 59.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ENTX +11.07%
LYRA -94.34%
Spread: +36.96 pp (ENTX Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ENTX Revenue | LYRA Revenue | ENTX Op. Margin | LYRA Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2020 | $0M | N/A | -3059.7% | N/A | ENTX |
| FY2021 | $0M | $0M | -2139.6% | -15303.5% | ENTX |
| FY2022 | $0M | $0M | -9714.2% | -4131.0% | LYRA |
| FY2023 | N/A | $0M | N/A | -4308.1% | LYRA |
| FY2024 | $0M | $0M | -5295.6% | -6280.8% | ENTX |
| FY2025 | $0M | $0M | -27450.0% | -7794.5% | LYRA |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ENTX | LYRA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $541.6M | $2.3M | Larger Scale | ENTX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -100.0% | -87.2% | Higher Growth | LYRA |
| Operating Margin (TTM) Profitability | 0.0% | -25032.0% | Higher Margin | ENTX |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -20.3% | -404.5% | Higher ROE | ENTX |
| 52-Week Range Position Momentum | 64% ($1โ$4) | 1% ($0โ$38) | Stronger Trend | ENTX |
| Beta / 30D Volatility Risk Regime | 1.07ฮฒ ยท 45% Vol | 0.33ฮฒ ยท 248% Vol | Lower Realized Risk | ENTX |
| Unified Institutional Score Composite Signal | 53.5 / 100 (HOLD) | 52.2 / 100 (HOLD) | Higher Composite | ENTX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ENTX vs LYRA Buy Guide
ENTX
CONSOLIDATION
80d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
32nd %ile
IV Regime
Balanced (25thโ60th %ile)
LYRA
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ENTX nor LYRA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.